OncoMatch/Clinical Trials/NCT06104592
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
Is NCT06104592 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Chimeric Antigen Receptor T-Cell Therapy for large b-cell lymphoma.
Treatment: Chimeric Antigen Receptor T-Cell Therapy — This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: CAR-T cell therapy
Prior treatment with chimeric antigen receptor (CAR) T-cell therapy
Cannot have received: investigational agent
currently receiving or who have received any other investigational study agent ≤4 weeks prior to screening visit
Lab requirements
Blood counts
Adequate bone marrow and organ function as defined in protocol
Kidney function
Adequate bone marrow and organ function as defined in protocol
Liver function
Adequate bone marrow and organ function as defined in protocol
Adequate bone marrow and organ function as defined in protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify